echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Innovative therapy targeting Nobel Prize signaling pathway in renal cell carcinoma, disease control rate reached 98%

    Innovative therapy targeting Nobel Prize signaling pathway in renal cell carcinoma, disease control rate reached 98%

    • Last Update: 2022-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, the results of phase 2 clinical trials of the hypoxia-inducible factor inhibitor belvutifan developed by Merck & Co.


    VHL is a rare genetic disease that abnormally activates hypoxia-inducible factor (HIF-2α) in cancer patients


    The results published in the "New England Journal of Medicine" showed that of the 61 patients with renal cell carcinoma treated, 30 (49%) achieved partial remission, and 30 patients (49%) had stable disease


    ▲Belzutifan's Phase 2 clinical trial data (picture source: reference [1])

    The 61 patients who participated in the trial also had lesions in other parts of the body.


    In the discussion, the researchers pointed out that the usual treatment for tumors associated with VHL disease is to use surgery to reduce the risk of metastatic disease


    Note: The original text has been deleted

    Reference materials:

    [1] Jonasch et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.